Literature DB >> 18413793

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.

Shu-Chuan Weng1, Yoko Kashida, Samuel K Kulp, Dasheng Wang, Robert W Brueggemeier, Charles L Shapiro, Ching-Shih Chen.   

Abstract

Tamoxifen is a mainstay in the treatment of estrogen receptor (ER)-positive breast cancer patients. Although the efficacy of tamoxifen has been attributed to induction of tumor cell growth arrest and apoptosis by inhibition of ER signaling, recent evidence indicates that tamoxifen possesses ER-independent antitumor activities. Here, we use OSU-03012, a small-molecule inhibitor of phosphoinositide-dependent protein kinase-1 (PDK-1) to address the hypothesis that PDK-1/Akt signaling represents a therapeutically relevant target to sensitize ER-negative breast cancer to tamoxifen. OSU-03012 sensitized both ER-positive MCF-7 and ER-negative MDA-MB-231 cells to the antiproliferative effects of tamoxifen in an ER-independent manner. Flow cytometric analysis of phosphatidylserine externalization revealed that this augmented suppression of cell viability was attributable to a marked enhancement of tamoxifen-induced apoptosis by OSU-03012. Mechanistically, this OSU-03012-mediated sensitization was associated with suppression of a transient tamoxifen-induced elevation of Akt phosphorylation and enhanced modulation of the functional status of multiple Akt downstream effectors, including FOXO3a, GSK3alpha/beta, and p27. The growth of established MDA-MB-231 tumor xenografts was suppressed by 50% after oral treatment with the combination of tamoxifen (60 mg/kg) and OSU-03012 (100 mg/kg), whereas OSU-03012 and tamoxifen alone suppressed growth by 30% and 0%, respectively. These findings indicate that the inhibition of PDK-1/Akt signaling to sensitize ER-negative breast cancer cells to the ER-independent antitumor activities of tamoxifen represents a feasible approach to extending the use of tamoxifen to a broader population of breast cancer patients. Considering the urgent need for novel therapeutic strategies for ER-negative breast cancer patients, this combinatorial approach is worthy of continued investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413793     DOI: 10.1158/1535-7163.MCT-07-0434

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  33 in total

Review 1.  Deciphering the role of forkhead transcription factors in cancer therapy.

Authors:  Jer-Yen Yang; Mien-Chie Hung
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

Review 2.  RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.

Authors:  Hemant K Bid; Ryan D Roberts; Parmeet K Manchanda; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2013-09-26       Impact factor: 6.261

Review 3.  A new fork for clinical application: targeting forkhead transcription factors in cancer.

Authors:  Jer-Yen Yang; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

4.  Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways.

Authors:  Jau-Chen Lin; Shuenn-Chen Yang; Tse-Ming Hong; Sung-Liang Yu; Qian Shi; Linyi Wei; Hsuan-Yu Chen; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

5.  Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.

Authors:  Tina X Lee; Mark D Packer; Jie Huang; Elena M Akhmametyeva; Samuel K Kulp; Ching-Shih Chen; Marco Giovannini; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Eur J Cancer       Date:  2009-04-07       Impact factor: 9.162

6.  Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.

Authors:  Haiming Ding; Chunhua Han; Dongmei Guo; Dasheng Wang; Wenrui Duan; Ching-Shih Chen; Steven M D'Ambrosio
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

7.  Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent.

Authors:  Hao-Chieh Chiu; Samuel K Kulp; Shilpa Soni; Dasheng Wang; John S Gunn; Larry S Schlesinger; Ching-Shih Chen
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

8.  ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Authors:  Subrata Manna; Josefine Bostner; Yang Sun; Lance D Miller; Anya Alayev; Naomi S Schwartz; Elin Lager; Tommy Fornander; Bo Nordenskjöld; Jane J Yu; Olle Stål; Marina K Holz
Journal:  Clin Cancer Res       Date:  2015-11-05       Impact factor: 12.531

Review 9.  ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.

Authors:  Jin-Qiang Chen; Jose Russo
Journal:  Biochim Biophys Acta       Date:  2009-06-13

10.  Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent.

Authors:  Hao-Chieh Chiu; Shilpa Soni; Samuel K Kulp; Heather Curry; Dasheng Wang; John S Gunn; Larry S Schlesinger; Ching-Shih Chen
Journal:  J Biomed Sci       Date:  2009-12-09       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.